Introduction
Doxorubicin (Dox) is widely used in cancer treatment, however, its clinical application is limited due to its side effects, notably cardiac toxicity.
1,2 P-gp is a notorious transmembrane bump, critically involved in tumor cell resistance to Dox. 3 The increasing expressions of P-gp promote tumor cell ability to efflux a wide range of cytotoxic agents, which leads to treatment failure. 4 Polymeric nano-carriers (NCs) have been reported as promising carriers of many anticancer drugs, 5, 6 due to their function as sustained, controlled and targeted drug delivery systems. [7] [8] [9] [10] By modifying the size and the surface charge, we designed a type of dextran-based nanogel with high biocompatibility and biosafety, which can be retained for a long time in lymph nodes. 11 The aim of this study was to develop Dox-loaded 
Materials and methods Materials
Dextran (molecular weight [Mw]=40,000 Da), ceric ammonium nitrate, and methyl acrylate were purchased from Shanghai Sinopharm Chemical Reagent Co., Ltd. (Huangpu District, Shanghai, China) and purified as described previously. 12 Diallyl disulfide (Sigma Aldrich, St Louis, MO, USA) was used after vacuum distillation. Doxorubicin hydrochloride (Dox) was purchased from Beijing Zhong Shuo Pharmaceutical Technology Development Co., Ltd. (Dongcheng, Beijing, China).
Preparation
Dox-NCs were fabricated through self-assembly assisted polymerization approach, as previously developed. [11] [12] [13] Two steps were included in the self-assembly assisted polymerization approach. The first step was the fabrication of dextranbased NCs bearing redox sensitive disulfide crosslinking junctions via a highly efficient self-assembly assisted approach developed by our group. Specifically, 2.5 g of dextran was fully dissolved in 50 mL of water and kept under N 2 protection at 30°C. Then initiator ceric ammonium nitrate (1.208 g dissolved in 1.25 mL of 0.1 M HNO 3 ) was added, and 5 minutes later the monomer, methyl acrylate (1.34 mL), was added into the solution. After 30 minutes, the cross-linker diallyl disulfide (0.244 mL dissolved in 1 mL of DMSO) was added into the system. The entire process was allowed to proceed for 4 hours and dialyzed against deionized water for 3 days. Finally, the solution was freeze-dried to obtain NCs. The second step involved Dox being covalently conjugated to NCs via a hydrazone bond through the same method as previously reported. 12 characterization Hydrodynamic diameter and zeta potential were measured using a Zetasizer Nano ZS90 instrument (Malvern Panalytical, Malvern, UK). Transmission electron microscopy (TEM) images were characterized using a JEM-2100 (JEOL Ltd., Akishima, Tokyo, Japan) instrument.
1 H NMR spectra were recorded by an Avance III 400 MHz spectrometer (Bruker, Faellanden, Switzerland). The Dox content and in vitro drug release was determined via the UV-Vis absorbance method using a Shimadzu UV-2550 UV-Vis spectrophotometer (Shimadzu, Tokyo, Japan) (the concentration of Dox-NCs was 0.5 mg/mL). 12 
cells and reagents
Human lymphoma cell lines, Jurkat, H9, Namalwa, and SU-DHL-4, as well as a rat cardiac cell line H9C2 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the manufacturer's recommendations. In order to achieve hypoxic conditions, cells were cultured in a hypoxia chamber with 1% oxygen. Dox-resistant cells were created by continuously exposing the cells to increasing concentrations of Dox, as previously reported. 14 
cell viability
Cell viability was assessed using a Cell Counting Kit-8 (Dojindo Laboratories, Tokyo, Japan), and absorbance was measured at 450 nm by spectrophotometry.
aTP assay
The ATP assay was performed as previously described. 15 Cells were incubated either with Dox or with Dox-NCs, for 24 hours and 48 hours. Intracellular ATP levels were detected using an ATP assay kit (Beyotime Biotechnology, Jiangsu, China); cells were lysed using the lysis buffer and centrifuged at 12,000 ×g for 5 minutes at 4°C. Fifty microliters of supernatant was mixed immediately with 100 µL of dilution buffer containing luciferase which had been preincubated at room temperature for 3 minutes. Luminance (RLU) was determined by using a Luminometer (Berthold Technologies, Bad Wildbad, Germany). The concentration of ATP was calculated using a previously determined standard curve and normalized using the cellular protein level. 
Flow cytometry
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Dox-loaded dextran-based Ncs inhibit lymphoma with reduced cardiac toxicity cells were washed with PBS three times, and the intracellular fluorescence of Dox was evaluated by flow cytometry at an excitation of 595 nm. 16 Terminal deoxytransferase-catalyzed DNa-nick-end labeling (TUNel) assay
In situ cell apoptosis was confirmed by detection of fragmented DNA, using the TUNEL assay, using the DeadEnd™ Colorimetric TUNEL System (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions. 17 
Western blot
Cells were lysed in 200 µL lysis buffer (0.5 M Tris-HCl, pH 6.8, 2 mM EDTA, 10% glycerol, 2% SDS and 5% β-mercaptoethanol). Electrophoresis was performed on 10% SDS polyacrylamide gels using samples with a concentration of 20 µg protein and transferred to nitrocellulose membranes. Membranes were blocked with 5% non-fat dried milk in Tris-buffered saline and incubated for 2 hours at room temperature with an appropriate primary antibody (caspase-3, cleaved caspase-3, survivin, P-gp), followed by the horseradish peroxidase-conjugated secondary antibody (goat anti-mouse-IgG and goat anti-rabbit-IgG). The immunocomplexes were visualized using the chemiluminescence phototope-horseradish-peroxidase kit (Cell Signaling Technology, Beverly, MA, USA). Actin was used to ensure equivalent protein loading. Horseradish peroxidaseconjugated goat anti-mouse-IgG and goat anti-rabbit-IgG antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Murine model
Nude mice (5-6-weeks-old) were obtained from Shanghai Laboratory Animal Center and injected subcutaneously with 4×10 7 Jurkat or 7×10 6 Namalwa cells into the right flank. Tumor volumes were calculated as 0.5× a×b, 2 where "a" is the length and "b" is the width. Treatment was started after the tumor measured ~0.5×0.5 (length × width) cm in surface on Day 0. The mice were divided into treatment groups, consisting of 10 mice per group. The mice in the untreated group were only given RPMI-1640, whereas the mice in the Dox group were administered an intraperitoneal injection of Dox (6 mg/kg, twice a week) and the mice in the Dox-NCs group were administered an intraperitoneal injection of DoxNCs (6 mg/kg, twice a week), for 2 weeks. The Shanghai Rui Jin Hospital Animal Care and Use Committee approved the experiments, which were conducted in accordance with their approved protocols.
Pathological analysis
Mice were euthanized at day 14, and subcutaneous tumors and hearts were dissected and cut into two parts. The samples were then prepared in 2 ways; (i) immediately snap frozen; (ii) formaldehyde-fixed and paraffin-embedded for analysis. Immunohistochemistry was performed on 5 µm-paraffin tumor sections using the indirect immunoperoxidase method and antibodies against Ki67 (DAKO, Glostrup, Denmark) and P-gp. The TUNEL assay was performed on the tumor and heart samples to determine the degree of cellular apoptosis.
statistical analysis
All assays were set up in triplicate and the results were expressed as the mean ± SD of data obtained from three separate experiments. Student's t-test was applied to compare two normally distributed groups and Bonferroni to perform multiple comparisons. P,0.05 was considered statistically significant. All statistical analyses were evaluated using Statistical Package for the Social Sciences (SPSS) 13.0 software (SPSS Inc., Chicago, IL, USA).
Results
characterization of Dox-Ncs
First, NCs were fabricated using a modified self-assembly assisted polymerization method. Successful preparation of the NCs was verified by an absorption signal at 1,732 cm −1 exhibited by Fourier transform infrared spectroscopy ( Figure 1A ). This absorption signal corresponded to the ester bonds in the poly(methyl acrylate) chains. The NCs exhibited a uniform spherical shape with a diameter of ~45 nm under TEM observation ( Figure 1B ) and a zeta potential of −3.8 mV. In the second step, the NCs were conjugated with Dox, the color of the solution changed from milky white to red, the diameter of NCs increased to ~65 nm ( Figure 1C ) and the zeta potential was −28.5 mV. UVabsorbance measurements revealed that the Dox-NCs exhibited a drug loading content of ~11.2 wt% ( Figure 1D ). In vitro drug release behavior of Dox-NCs is shown in Figure 1E . The cumulative drug release from the NCs reached ~35% at a pH of 5.0 with 10 mM GSH. However, the drug release rate was only ~16% at a pH of 7.4.
Dox-Ncs increased intracellular Dox concentration and lymphoma cell cytotoxicity
To mimic in vivo hypoxia inside the tumor lymphoma, cell lines Jurkat, H9, Namalwa and SU-DHL-4 were cultured under hypoxic conditions and exposed to either Dox-NCs Fang et al or Dox for 7 days. Intracellular Dox concentrations were detected at indicated time points. At 36 hours, the fluorescence intensity markedly increased and remained higher in the Dox-NCs-treated cells, when compared with Doxtreated cells (Figure 2A) Figure 2B ), in consistent with the growth inhibition curves ( Figure 2C ).
Dox-Ncs induced lymphoma cell apoptosis through downregulating survivin
Apoptosis, a type of programmed cell death, is usually used as an indicator of treatment efficacy. As revealed by TUNEL assay and Annexin-V analysis, Dox-NCs markedly increased apoptosis in both Jurkat and Namalwa cells, when compared with Dox treatment (Figure 3A and B) . Caspase-3 activation, accompanied by the inhibition of the anti-apoptotic molecule survivin, were observed as the mechanisms of action in the Dox-NC treated cells ( Figure 3C ).
Dox-Ncs inhibited P-gp induction and induced Dox-resistant cell apoptosis
Accumulating evidence has shown that Dox-treatment could induce tumor cell P-gp expression, resulting in increased drug excretion and multidrug resistance. 18, 19 Compared with Dox, Dox-NCs inhibited P-gp expression ( Figure 4A ). As the mechanism of action, cytoplasmic ATP concentration was significantly lower, after 48 hours incubation, in Dox-NCs-treated cells (Jurkat 0.63±0.11 nmol/10 6 cells, Namalwa 0.71±0.29 nmol/10 6 cells), when compared with Dox-treated cells (Jurkat 1.34±0.11 nmol/10 6 cells, Namalwa 1.66±0.22 nmol/10 6 cells, P,0.05, Figure 4B ). Acquired Figure 4C ), but also increased apoptosis of the Dox-resistant cells ( Figure 4D ).
Dox-Ncs exhibited in vivo anti-lymphoma activity with less cardiac toxicity
The in vivo anti-tumor activity of Dox-NCs was further evaluated in murine xenograft models. Subcutaneous inoculation of Jurkat or Namalwa cells into nude mice resulted in tumor formation at the injection sites of all the mice. The sizes of tumors formed in Dox-NC treated mice were significantly smaller than those of the control group and Dox group after 14 days of treatment (P,0.0001, Figure 5A ). Consistent with the in vitro study, the expression of P-gp and Ki67 were lower in the Dox-NC-treated tumor cells than those with Dox. (Figure 5B ). However, TUNEL assay showed that apoptotic tumor cells were more abundant in the Dox-NCs group than in the Dox group ( Figure 5B ). On the other hand, the mice in the Dox-NC group demonstrated less weight loss than those in the Dox group; which is indicative of low treatment toxicity with Dox-NCs ( Figure 5A, left panel) . Cardiac toxicities are the most important adverse effect of Dox. Compared with the Dox group, mice treated with Dox-NCs had less apoptosis of cardiac cells as revealed by hematoxylineosin staining and TUNEL assay ( Figure 5C ). Further in vitro 
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Fang et al studies showed that the intracellular concentration of Dox was significantly lower in the Dox-NC treated cardiac cell line H9C2, than the Dox-treated cells. In conjunction with the intracellular Dox concentration, reduced apoptotic cells (11.3%±5.6%) were found with the Dox-NC treated cells, when compared with those treated with Dox (30.2%±4.3%, P,0.05, Figure 5D ).
Discussion
To our knowledge, this is the first report evaluating the dualstimulus response of Dox-NCs, which significantly enhanced lymphoma cell growth inhibition, even in Dox-resistant cells. Additionally, Dox-NCs showed less toxicity towards normal cardiac cells. Since Dox-NCs are comprised of both redox sensitive disulfide crosslinking junctions and acid-labile 
5679
Dox-loaded dextran-based Ncs inhibit lymphoma with reduced cardiac toxicity hydrazone bonds (−28.5 mV), Dox-NCs can display a 2-fold release ratio of the drug in mimicked tumor site conditions (pH 5.0 with 10 mM GSH), as well as in the mimicked systemic circulation conditions (pH 7.4). This contributed to the accelerated drug release behavior in the mimicked tumor site conditions. The disulfide crosslinking units within NCs were cleaved in a reductive environment and the subsequent hydrazone bond was broken in an acidic environment. [20] [21] [22] NC size and membrane charge are important factors for the molecules to selectively enter the lymphatic system, 23, 24 which is also known as passive selection. We have constructed optimal dextran-based NCs for lymph node mapping. 11 Based on this technique, the Dox-NCs, with narrowly dispersed spherical shape (~65 nm), were successfully prepared. These features enabled Dox-NCs to be passively selected, and retained, in the lymphatic system, which might be a potential option for lymphoma treatment.
Since high glucose uptake is a characteristic of cancer cells, polysaccharide coating can increase cellular uptake. 25 This may explain why Dox-NCs enter the plasma of lymphoma cells more efficiently than Dox. Moreover, it is reported that modification of the drug loading system not only provokes cytotoxicity but also suppresses P-gp expression. 26 Here our data also showed that Dox coated 
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Dox-loaded dextran-based Ncs inhibit lymphoma with reduced cardiac toxicity Figure 5 In vivo effects of Dox-Ncs in murine lymphoma xenograft models. Notes: (A) In both T-and B-cell lymphoma xenograft models, intraperitoneal treatment of Dox-NCs significantly inhibited tumor growth without affecting the weight of the mice. *P,0.05, **P,0.01, ***P,0.001 compared with Dox. (B) as compared with the Dox group, decreased proliferative index Ki67 and low expression of P-pg were observed in the tumors of the Dox-NC group. TUNEL assay showed that Dox-NCs enhanced tumor apoptosis significantly. Scale bar set at 100 µm. (C) hematoxylin-eosin staining and TUNel assay revealed diminished apoptosis of cardiac cells by Dox-Ncs in vivo. scale bar set as 100 µm (D) Dox-Ncs induced cellular apoptosis to a lesser degree in cardiac cell line h9c2 than Dox. ***P,0.0001 compared with Dox. scale bar set as 100 µm. (E) Dox-loaded dextran-based NCs are an efficient drug delivery system to treat malignant lymphoma with less cardiac toxicities. Abbreviations: Dox, doxorubicin; h, hours; Ncs, nano-carriers; TUNel, terminal deoxytransferase-catalyzed DNa-nick-end labeling assay.
with dextran increased cellular uptake and inhibited P-gp expression, blocking excretion of the drug, which in turn led to increased cellular Dox concentrations. Consequently, the high intracellular concentration of Dox, inhibition of tumor growth and induction of apoptosis were more prominent in Dox-NCs-treated lymphoma cells. Overexpression of P-gp promotes cell resistance to Dox and induces multidrug insensitivity. In the present study, Dox-NCs effectively killed the isogenic Dox-resistant cells with high P-gp expression, which is significant for clinical application. While being highly toxic to tumor cells, Dox-NCs proved to be a safer treatment option inducing less weight loss in the mice than Dox. In the circulation, toxic Dox was encapsulated by dextran, which is non-toxic to normal cells. A lower cellular uptake of Dox-NCs by cardiac cells resulted in lower toxicity, which is advantageous in that it reduces the side effects on normal organs. 27 
Conclusion
We concluded that Dox-loaded dextran-based NCs are efficient drug delivery systems to treat malignant lymphoma with less cardiac toxicity.
